Archives de l’auteur : Marianne Duparc
Universal Flu Vaccine Candidate Shows Promise in Mid-Stage Trial — Efficacy in range of NIH target, exploratory analysis finds
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836 OVX836 demonstrated positive safety and immunogenicity data across three dose levels A notable signal of protection of 84% was observed against symptomatic influenza infection Lyon, France – July 28, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide …
OVX-033 vaccine exhibits broad protection against SARS-CoV-2 in preclinical models
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033 in Frontiers in Immunology
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033in Frontiers in Immunology Evidence of cross-protection against multiple SARS-CoV-2 variants of concern observed in hamster challenge model Lyon, France – July 06, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the publication of promising preclinical …
Race for universal flu vaccine ramps up as Osivax kicks off Phase IIa trial
Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs Australia-based Phase 2a clinical study to evaluate broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs) An enrollment of over 500 participants across Australia is anticipated Lyon, France – June 15, 2023 – Osivax, a biopharmaceutical company developing …
World Congress Vaccine Washington 2023
Washington, DC – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Phase 2 immunogenicity results on OVX836 first-in-class broad-spectrum influenza vaccine in elderly patients”.
En bref : Cellprothera, Osivax, Confo Therapeutics, Daiichi Sankyo
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers …